Kazakhstan Medical Device Registration: Five-layer Total Cost Model

1. Key takeaways

The total cost of a Kazakhstan project should be modeled in five layers: official registration-side fees, comprising the state duty of 11 MRP, equal to 47,575 tenge, re-registration at 5 MRP, equal to 21,625 tenge, plus expert review fees under Order No. ҚР ДСМ-7; testing and research fees, covering technical testing, toxicological studies, samples and shipping; manufacturing site inspection fees, covering travel and institutional charges; localization and agency fees, covering bilingual conversion, representative services, submission and sample follow-up; and circulation-side tax, with VAT at 5 percent in 2026 and 10 percent from 2027. The first four layers are one-off costs while the fifth is recurring; mixing them in one table underestimates the long-term cost. The practical estimate is that the official duty line, though the easiest to verify, accounts for only a small fraction of the total, so the model must be driven by the variable layers rather than by the fixed one.

2. Legal basis

3. Expert insights

Insight one: one-off and recurring costs must be separated; this is the first principle of cost modeling. The registration duty, expert fees, testing fees and inspection fees are one-off. VAT, annual representative fees, periodic inspections, where the report is valid for 3 years and a new inspection is needed on expiry, and maintenance of the post-market monitoring system are recurring. Mixing the two leads to the mistaken conclusion that Kazakhstan is cheap. The correct reading is that entry is comparatively affordable while staying in the market carries a steady annual load, and portfolio decisions such as how many models to register should be made against that steady load.

Insight two: Government Resolution No. 542 expanded the product categories eligible for the preferential rate, a major change for 2026. Resolution No. 542 of June 24, 2026 clarified the VAT preferential treatment in the medical field and brought diagnostic products, medical consumables, production equipment, pharmaceutical manufacturing raw materials and industrial auxiliary materials within the scope of the preferential rate. Companies making IVD products and consumables should recalculate this item. For importers, the resolution changes the VAT line in landed cost calculations, and for distributors it changes margins on exactly the categories that move in the highest volumes.

Insight three: inspection cost is a one-off cost with a cycle. Under Decision No. 106, the inspection conclusion report is valid for 3 years, and periodic inspections recur every 3 years. It is neither purely one-off, since it repeats, nor fully recurring, since it is not annual. In modeling it should be treated as an annuity on a 3-year cycle. The practical estimate for each cycle should include not only the inspection fee itself but also travel, document preparation and any remediation work identified during the previous inspection.

Insight four: bilingual conversion costs in Kazakhstan are significantly higher than in single-language markets. Labels, outer packaging and instructions for use must be in both Russian and Kazakh, and the registration dossier also contains a list of bilingual documents. Translation and review workload is roughly double that of a single-language market, and terminology glossary maintenance is an additional process step. The bilingual requirement also applies to labeling changes, so every future label revision inherits the double workload unless templates are standardized early.

Insight five: the choice of pathway changes the cost structure. The national pathway can accept foreign clinical data, saving the cost of clinical studies conducted inside the Union; the Union pathway covers five member state markets in one procedure, diluting the cost per market. The ratio of one-off to recurring costs differs completely between the two routes, so both should be quantified before commitment.

4. Practical recommendations

1. Build a five-layer cost model with one-off and recurring costs listed separately, and output totals on both 3-year and 5-year horizons.
2. Model VAT on a stepped basis, at 5 percent in 2026 and 10 percent from 2027, and assess the impact of the category expansion under Resolution No. 542.
3. Treat inspection fees as an annuity on a 3-year cycle and include them in the long-term budget.
4. Estimate bilingual conversion costs at twice the level of a single-language market and include glossary maintenance workload.
5. Produce a comparison of two cost models at the pathway selection stage so that only one route is never calculated.

5. Verification checklist

• □ A five-layer cost model has been built, covering duties, testing, inspection, localization and tax
• □ One-off and recurring costs are listed separately, with 3-year and 5-year totals produced
• □ VAT has been modeled on the stepped basis from 5 to 10 percent
• □ The category expansion under Resolution No. 542 has been assessed, covering diagnostic products, consumables and production equipment
• □ Inspection fees have been treated as an annuity on a 3-year cycle
• □ A comparison of cost models for the national and Union pathways has been produced

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, including full life cycle cost modeling and pathway comparison. Cost models are delivered on 3-year and 5-year horizons with one-off and recurring layers separated. For inquiries, contact info@grzanglobal.com.